Ipca Laboratories Merger & Restructuring Worth ₹7,431 Cr

Ipca Laboratories Board Meeting Date

Ipca Laboratories board meeting set for 5 November 2026 to approve Q2 and H1 FY27 unaudited results. Insider trading window remains closed until two days after declaration.

Ipca Laboratories Other Announcement

Ipca Laboratories Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with Regulation 31(1)(b) of the SEBI Listing Regulations.

Ipca Laboratories Earnings Call Transcript: Key Takeaways

Ipca reported strong Q1FY27 with 21% consolidated revenue growth and EBITDA margins expanding 449bps to 22.88%. Management raised full-year growth and margin guidance based on robust generic and domestic performance.

Call

Guides 16% growth

Ipca Laboratories Annual General Meeting

Ipca Laboratories held its 76th Annual General Meeting, covering the adoption of financial statements, dividend declaration, and director appointments. No voting results were included.

Ipca Laboratories Q1 FY27 Results: Net Profit ₹424.3 Cr, Up 82.2% YoY

Ipca Laboratories Ltd reported revenue from operations of ₹2,788 Cr (+20.8% YoY) and net profit of ₹424.3 Cr (+82.2% YoY) for Q1 FY27.

Key figure

Net profit ₹424.3 Cr · +82.2% YoY

Ipca Laboratories Board Meeting Date

Ipca Laboratories scheduled a Board meeting for August 13, 2026. The board will consider standalone and consolidated financial results for the first quarter.

Quint Digital Merger & Restructuring

Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.

Hexaware Technologies Merger & Restructuring

Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.

Execution

Expected completion by 30 June 2027; agreement date stated as 1 December 2026

Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr

Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.

Value

₹2.75 Cr

Execution

Completion expected by 26 January 2027

TVS Holdings Merger & Restructuring

TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.

Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr

Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.

Value

₹30.00 Cr

Execution

Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals

Fortis Healthcare Merger & Restructuring Worth ₹277 Cr

Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.

Value

₹277.0 Cr